Zevalin News and Research

RSS
Zevalin is a monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate. Also called ibritumomab tiuxetan.
CTI reports financial results for fourth-quarter and year ended December 31, 2009

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Zevalin clinical data presented at 2009 ASH meeting

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Monoclonal antibody cancer therapy

Monoclonal antibody cancer therapy

Cell Therapeutics targeting potential Zevalin label expansion,

Cell Therapeutics targeting potential Zevalin label expansion,

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application

New discoveries in treatment for patients with non-Hodgkin's lymphoma

New discoveries in treatment for patients with non-Hodgkin's lymphoma

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Zevalin safe and effective for non-Hogdkin's lymphoma patients

Zevalin safe and effective for non-Hogdkin's lymphoma patients

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma